Verrica Pharmaceuticals Earnings Estimate

VRCA Stock  USD 5.64  0.01  0.18%   
The next projected EPS of Verrica Pharmaceuticals is estimated to be -0.83125 with future projections ranging from a low of -1.125 to a high of -0.65. Verrica Pharmaceuticals' most recent 12-month trailing earnings per share (EPS TTM) is at -11.4. Please be aware that the consensus of earnings estimates for Verrica Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
Verrica Pharmaceuticals is projected to generate -0.83125 in earnings per share on the 31st of December 2025. Verrica Pharmaceuticals earnings estimates show analyst consensus about projected Verrica Pharmaceuticals EPS (Earning Per Share). It derives the highest and the lowest estimates based on Verrica Pharmaceuticals' historical volatility. Many public companies, such as Verrica Pharmaceuticals, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm.

Verrica Pharmaceuticals Revenue Breakdown by Earning Segment

By analyzing Verrica Pharmaceuticals' earnings estimates, investors can diagnose different trends across Verrica Pharmaceuticals' analyst sentiment over time as well as compare current estimates against different timeframes. The current year's Gross Profit Margin is expected to grow to 0.96, whereas Gross Profit is forecasted to decline to about 3.6 M. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verrica Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
For information on how to trade Verrica Stock refer to our How to Trade Verrica Stock guide.

Verrica Pharmaceuticals Earnings Estimation Breakdown

The calculation of Verrica Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Verrica Pharmaceuticals is estimated to be -0.83125 with the future projection ranging from a low of -1.125 to a high of -0.65. Please be aware that this consensus of annual earnings estimates for Verrica Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
0.0
-1.12
Lowest
Expected EPS
-0.83125
-0.65
Highest

Verrica Pharmaceuticals Earnings Projection Consensus

Suppose the current estimates of Verrica Pharmaceuticals' value are higher than the current market price of the Verrica Pharmaceuticals stock. In this case, investors may conclude that Verrica Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Verrica Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of December 2025Current EPS (TTM)
476.02%
0.0
-0.83125
-11.4

Verrica Pharmaceuticals Earnings per Share Projection vs Actual

Actual Earning per Share of Verrica Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Verrica Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Verrica Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Verrica Pharmaceuticals Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Verrica Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Verrica Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.

Verrica Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Verrica Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
null
nullnullnullnull
null
nullnullnullnull
2025-05-12
2025-03-31-0.136-0.10.03626 
2025-02-26
2024-12-31-0.242-0.20130.040716 
2024-11-07
2024-09-30-0.37-0.49-0.1232 
2024-08-14
2024-06-30-0.42-0.370.0511 
2024-05-13
2024-03-31-0.4-0.44-0.0410 
2024-02-29
2023-12-31-0.53-0.530.0
2023-11-09
2023-09-30-0.36-0.54-0.1850 
2023-08-08
2023-06-30-0.21-0.24-0.0314 
2023-05-09
2023-03-31-0.19-0.150.0421 
2023-03-06
2022-12-31-0.19-0.140.0526 
2022-11-07
2022-09-30-0.110.030.14127 
2022-08-11
2022-06-30-0.32-0.37-0.0515 
2022-05-09
2022-03-31-0.47-0.310.1634 
2022-03-02
2021-12-31-0.5-0.350.1530 
2021-11-12
2021-09-30-0.51-0.470.04
2021-08-10
2021-06-30-0.41-0.43-0.02
2021-05-07
2021-03-31-0.35-0.040.3188 
2021-03-04
2020-12-31-0.42-0.52-0.123 
2020-11-09
2020-09-30-0.43-0.420.01
2020-08-05
2020-06-30-0.45-0.380.0715 
2020-05-07
2020-03-31-0.38-0.39-0.01
2020-03-13
2019-12-31-0.29-0.31-0.02
2019-11-06
2019-09-30-0.27-0.240.0311 
2019-08-07
2019-06-30-0.3-0.280.02
2019-05-07
2019-03-31-0.28-0.3-0.02
2019-03-07
2018-12-31-0.27-0.3-0.0311 
2018-11-07
2018-09-30-0.24-0.27-0.0312 
2018-08-07
2018-06-30-0.28-1.04-0.76271 
2018-06-15
2018-03-310-0.08-0.08
2018-02-03
2017-12-310-0.18-0.18
2017-05-04
2017-03-310-0.02-0.02

About Verrica Pharmaceuticals Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Verrica Pharmaceuticals earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Verrica Pharmaceuticals estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Verrica Pharmaceuticals fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-307 M-291.7 M
Retained Earnings Total Equity-147.1 M-154.5 M
Earnings Yield(2.11)(2.01)
Price Earnings Ratio(0.47)(0.50)
Price Earnings To Growth Ratio(0.05)(0.05)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Verrica Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Verrica Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Verrica Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Verrica Pharmaceuticals Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verrica Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
For information on how to trade Verrica Stock refer to our How to Trade Verrica Stock guide.
You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verrica Pharmaceuticals. If investors know Verrica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verrica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(11.40)
Revenue Per Share
1.124
Quarterly Revenue Growth
(0.10)
Return On Assets
(0.63)
Return On Equity
(15.47)
The market value of Verrica Pharmaceuticals is measured differently than its book value, which is the value of Verrica that is recorded on the company's balance sheet. Investors also form their own opinion of Verrica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Verrica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verrica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Verrica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verrica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Verrica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verrica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.